Decoy Therapeutics heads into a critical two-day window with a fresh earnings miss on the books and a major lock-up agreement expiring on May 11.
The most urgent catalyst is the lock-up. Over one million common shares — held by officers, directors, and related parties — come free from their 180-day lock-up restriction on Monday, May 11. That follows directly on the heels of Q1 results filed Thursday evening, where the company reported a net loss of $2.22 million and a basic EPS of -$4.18, narrowly missing the -$4.08 consensus estimate. Two catalysts colliding in the same 48-hour window makes this a week worth watching closely for a micro-cap trading at $5.72 and down 3% on the week.
The borrow market tells a surprisingly relaxed story given that backdrop. Short interest has fallen sharply — down 37% over the past month and 13% in the past week alone, now representing just 0.24% of the free float. That is not a heavily shorted stock. What remains striking, however, is the cost to borrow: at nearly 76% annualised, it is punishingly expensive to maintain a short position despite the thin short base. Borrow availability has loosened dramatically from earlier in the year — utilization peaked at 96.6% on the 52-week scale but has dropped to just under 3% — meaning there is now ample capacity to short if new sellers emerge, but few appear to be taking the trade at these rates.
The cost-to-borrow trajectory is telling in its own right. Rates spiked above 150% in mid-to-late March and remained above 100% through early April before falling to the current 75-76% range. That decline aligns directly with the retreat in short interest over the same period — borrowers have been returning shares, not adding them. The short score has drifted lower too, from 49.6 in late April to 45.5 today, reflecting an easing rather than building of short-side pressure.
There are no analyst ratings or price targets in the data for DCOY, consistent with a company at this early stage and market capitalisation of roughly $3 million. The EPS surprise factor score ranks at the 95th percentile, an artefact of the company's track record relative to (minimal) consensus estimates rather than a reflection of strong results. The DTC rank at 93 highlights how quickly any short position could be unwound — days-to-cover is just 0.08 — confirming the short interest angle is more about borrow cost than crowding. The stock is down 26.5% year-to-date and has a RSI-14 of 42.65, sitting in mildly oversold territory without being extreme.
The next scheduled event is May 12 — described as a further earnings results announcement, though Thursday's Q1 10-Q filing may already represent the substantive disclosure. Either way, the combination of a fresh EPS miss, an imminent lock-up expiry, and still-elevated borrow costs at nearly 76% APR makes the next 72 hours the most consequential near-term window for DCOY. The question is whether freed-up lock-up shares find any willing buyers at current levels.
See the live data behind this article on ORTEX.
Open DCOY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
